Biopharmaceutical company Sosei Group Corporation (TSE:4565) reported on Thursday that its strategic alliance partner Novartis (SWX: NOVN) has filed a valid Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) for the potential new inhaled combination asthma therapy QVM149.
Following the MAA filing, Sosei Heptares will now receive a USD2.5m payment from Novartis.
According to the company, QVM149 is an investigational, once-daily, fixed dose combination asthma treatment containing indacaterol acetate, glycopyrronium bromide and mometasone furoate (IND/GLY/MF), delivered with the dose-confirming Breezhaler inhalation device.
In 2005, glycopyrronium bromide and certain intellectual property relating to its use and formulation were exclusively licensed to Novartis by Sosei Heptares and Vectura Group PLC (LSE:VEC). Novartis is responsible for the development and commercialization of QVM149.
Currently, QVM149 is being investigated in Phase III/IIIb studies (IRIDIUM1 and ARGON2), which are expected to be completed in Q3 2019.
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
GSK's meningitis vaccine candidate accepted for FDA review
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study